Stocktoria
4D Molecular Therapeutics, Inc. FDMT
4D Molecular Therapeutics, Inc. (FDMT) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $85.2M at a -164.4% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.651 |
| Retained earnings / assets | -1.264 |
| EBIT / assets | -0.282 |
| Equity / liabilities | 8.283 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| FDMT | 4D Molecular Therapeutics, Inc. | 3/9 | 6.96 | — | — |
| MGTX | MeiraGTx Holdings plc | 2/9 | -14.65 | — | +144.6% |
| AUTL | Autolus Therapeutics plc | 2/9 | -6.27 | — | +644.9% |
| RXRX | RECURSION PHARMACEUTICALS, INC. | 3/9 | -1.13 | — | +26.9% |
| CGEN | COMPUGEN LTD | 6/9 | -0.84 | 5.6 | +161.1% |
| BDTX | Black Diamond Therapeutics, Inc. | 6/9 | -0.83 | 4.4 | — |
| VIR | Vir Biotechnology, Inc. | 2/9 | -0.97 | — | -7.6% |
About 4D Molecular Therapeutics, Inc.
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California.
FAQ
Is FDMT financially healthy?
4D Molecular Therapeutics, Inc.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does FDMT pay a dividend?
No, 4D Molecular Therapeutics, Inc. does not currently pay a dividend.
How profitable is FDMT?
In FY2025, 4D Molecular Therapeutics, Inc. had a net margin of -164.4% and a return on equity of -27.7%.
What is the analyst price target for FDMT?
The average Wall-Street price target for 4D Molecular Therapeutics, Inc. is $28.22, about 137.8% above the recent price, from 9 analysts.
Is FDMT a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on 4D Molecular Therapeutics, Inc.: a Piotroski F-score of 3/9, an Altman Z″ in the safe zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.